What is the history of Meningococcal vaccine use in America?
Meningococcal vaccine development in the United States began in the 1960s with the organization of a U.S. military meningococcal research group. 1 Throughout both World Wars, meningococcal disease outbreaks were noted and often impacted new recruits within their first three months of service. While meningococcal disease death rates had decreased as result of the discovery and use of sulfonamides by the late 1930’s, sulfa-resistant meningococcal strains had begun to emerge in the 1940s, leading military scientists to begin research on developing a meningococcal vaccine.2
The first polysaccharide vaccine targeting meningococcal serogroup C was developed by and tested on members of the U.S armed forces by early 1968. Military scientists also developed a meningococcal serogroup A polysaccharide vaccine, however, clinical trials of this vaccine took place in African communities where serogroup A meningococcal disease was found to be endemic.3
By October of 1971, all new U.S. Armed Forces recruits were required to receive the military’s meningococcal serogroup C vaccine, a vaccine not yet licensed for use by the FDA.4 It wasn’t until 1974 that the FDA licensed three meningococcal polysaccharide vaccines, but only for limited use. The first licensed vaccines included a monovalent meningococcal serogroup A vaccine, a monovalent meningococcal serogroup C vaccine, and a bivalent serogroup A and C vaccine. In 1975, the CDC’s Advisory Committee on Immunization Practices (ACIP) declined to routinely recommend the vaccines and stated that there was “insufficient data on their benefits.” 5 The vaccines were, however, recommended for use in the event of a meningococcal serogroup A or C outbreak but permission for use was required by both the FDA and CDC. Additionally, the CDC stated that while travelers visiting countries where meningococcal disease was considered endemic might benefit from vaccination, they also noted that no cases of meningococcal disease had ever been reported among Americans visiting these high risk areas.6 The military continued to routinely administer meningococcal polysaccharide serogroup C vaccine to all new recruits until 1978 at which time it switched to the bivalent meningococcal serogroup A and C polysaccharide vaccine.7
Menomune, the first tetravalent meningococcal polysaccharide vaccine targeting meningococcal serogroups A, C, Y and W-135 received FDA approval for use in 19818 and by 1982, the military began using this vaccine in place of the bivalent vaccine.9 In 1985, the CDC’s Advisory Committee on Immunization Practices (ACIP) issued their first recommendations on use of the tetravalent vaccine and recommended that the vaccine for individuals with terminal complement component deficiencies, functional or anatomical asplenia, or in the event of an outbreak of serogroup A, C, Y and W-135 meningococcal disease.10 In the spring of 2000, ACIP recommended college students, particularly college freshman living in dormitories, consider tetravalent meningococcal polysaccharide vaccination but chose not to recommend routine vaccination, stating that meningococcal disease rates were low and routine vaccination would not be cost effective.11
The first meningococcal conjugate vaccine, Menactra, manufactured by Sanofi Pasteur, received FDA approval in January 2005 for use in persons ages 11 through 55 years.12 Menactra (MCV4 or MenACWY-D), a vaccine conjugating meningococcal serogroups A, C, Y and W-135 to a diphtheria toxoid, received FDA approval on the basis that it was not inferior in both safety and immunogenicity to the available tetravalent meningococcal polysaccharide vaccine, Menomune. 13
Later that year, in May of 2005, the CDC’s Advisory Committee on Immunization Practices (ACIP) recommended that all 11-12 year olds receive the newly approved vaccine. In its recommendation, ACIP reported that a single vaccine dose would likely be effective for at least 22 years, and by vaccinating all 11-12 year olds, 21 cases and 3 deaths would be averted in the first year, and 270 cases and 36 deaths would be prevented over a period of 22 years. The committee also recommended the vaccine for use in persons between the ages of 11 and 55 with functional or anatomical asplenia and complement component deficiencies as well as for college freshman living in dormitories, military recruits, microbiologists routinely working with N. meningitidis, and persons traveling to or residing in meningococcal disease endemic countries.14 When the recommendation was made, the vaccine had only been studied in approximately 5,000 health adolescents, and only one study of just over 1,000 teenagers had evaluated the safety and immunogenicity of the vaccine when administered concomitantly with the tetanus-diphtheria (Td) vaccine.15 16
By September of 2005, the FDA and CDC issued a joint advisory warning of a potential association between Menactra vaccine and Guillain-Barre Syndrome (GBS).17 The vaccine product insert was updated to warn of the possible association of the vaccine to GBS and a previous history of GBS was listed as a contraindication to vaccination. The CDC, however, continued to recommend vaccination even as additional cases of GBS following Menactra vaccine administration were reported.18
In May of 2006, the CDC issued a recommendation to defer vaccination of all 11-12 year olds in anticipation of a vaccine shortage, however, vaccination of all adolescents entering high school and all college freshman residing in dormitories continued to be recommended.19 Despite a meningococcal vaccine shortage, reports of GBS following Menactra vaccine administration continued to be submitted to the Vaccine Adverse Events Reporting System (VAERS). The CDC issued another update on the additional cases of GBS following Menactra vaccine in October 2006 but continued to recommend vaccination, reporting that GBS rarely occurred and data evaluation of a link would take years to determine.20 In 2010, after a review of safety studies, the CDC’s Advisory Committee on Immunization Practices (ACIP) voted to remove a personal history of GBS as a contraindication to meningococcal vaccination, and stated that the vaccine’s benefits outweighed the possible risk of developing a recurrent case of GBS.21 The Menactra product insert, however, continues to caution that a previous diagnosis of GBS may increase a person’s chance for recurrent illness and the decision to administer Menactra should carefully consider both the possible risks and potential benefits to vaccination.22
By November 2006, the supply of Menactra vaccine had improved and routine vaccination of all 11-12 year olds was resumed along with continued vaccination of all high school freshman and college freshmen residing in dormitories. However, by November of 2006, additional vaccines targeting all 11-12 year olds had been both FDA approved and added to the CDC’s vaccine schedule by the Advisory Committee on Immunization Practices (ACIP). The newly licensed tetanus, diphtheria, and acellular pertussis vaccine (Tdap) was added in March of 200623 and in June of 2006, Gardasil, Merck’s human papillomavirus vaccine (HPV4) received FDA approval for use in all 11-12 year old females.24 When the ACIP published its recommendation on the HPV vaccine in March of 2007, it acknowledged that no evidence existed on the safety or effectiveness of administering the vaccine with Menactra or other newly recommended vaccines, however physicians were encouraged to simultaneously administer all recommended vaccines based on an assumption of safety.25 By August of 2007, the ACIP recommended that all adolescents between the ages of 11 and 18 be vaccinated with the meningococcal conjugate vaccine at the earliest opportunity as the vaccine supply was believed to be sufficient enough to handle the increased demand for the product anticipated by this updated recommendation.26
In October of 2007, the FDA approved Menactra (MCV4 or MenACWY-D) for use in children over the age of two. 27 One week later, the CDC’s Advisory Committee on Immunization Practices (ACIP) recommended that all children between the ages of 2 and 10 years with functional or anatomical asplenia, complement component deficiencies, as well as children traveling to meningococcal disease endemic areas be vaccinated with MCV4. The vaccine was also recommended over the previously approved meningococcal polysaccharide vaccine despite any evidence that it was more effective than the previously recommended meningococcal polysaccharide vaccine.28 In February 2008, the committee, however, declined to decrease the recommended age of routine MCV4 vaccination to include children as young as two years of age, reporting that the current strategy of vaccinating all 11-12 year olds was likely to be most cost effective.29
Menveo (MenACWY-CRM), a second meningococcal serogroup A, C, Y, and W-135 conjugate vaccine manufactured by Novartis Vaccine and Diagnostics (GlaxoSmithKline) received FDA approval in February of 2010 for use in persons aged 11 through 55 years.30 By March of 2010, the CDC’s Advisory Committee on Immunization Practices (ACIP) announced that MenACWY-CRM could be used when vaccination with a meningococcal conjugate vaccine was indicated.31 Only one pre-licensing clinical trial of Menveo examined the safety and effectiveness of administering the vaccine concomitantly with both Tdap and HPV vaccine. The clinical trial involved 540 females between the ages of 11 and 18, however, trial results were not required by the FDA prior to the vaccine’s approval.32
By October of 2010, public health officials had discovered that meningococcal conjugate vaccines were not as effective as previously thought. Meningococcal conjugate vaccines did not offer long-term vaccine acquired immunity and health officials reported that over 50 percent of teenagers vaccinated at age 11-12 years would likely not be protected against meningococcal disease when the risk of disease development was significantly higher, by age 16 through 21. As the CDC’s Advisory Committee on Immunization Practices (ACIP) had previously determined age 11-12 to be a time when adolescents were noted to have a greater number of preventative care visits and that recommending the vaccine at this age would “strengthen the pre-adolescent vaccination platform,” 33 a booster dose of meningococcal conjugate vaccine was recommended at age 16 in lieu of increasing the age recommendation to 16 years. The committee, however, stated that if the first dose of meningococcal conjugate vaccine was administered at age 16 or older, no additional booster dose would be required and that meningococcal vaccination of healthy individuals 21 years of age and older was not necessary due to the low risk of meningococcal disease in this population.34
In January of 2011, Menveo (MenACWY-CRM) received FDA approval for use in children age 2 through 10 years35 and in April of 2011, Menactra (MenACWY-D) was approved for use in infants and young children between the ages of 9 and 23 months.36 Following FDA approval, the CDC’s Advisory Committee on Immunization Practices (ACIP) voted to recommend Menactra (MenACWY-D) for use in infants and young children with complement component deficiencies, those traveling to areas where meningococcal disease was considered endemic, as well as those residing in an institution or community setting in the midst of a meningococcal outbreak. However, children with functional or anatomical asplenia, a population noted to be at greater risk for pneumococcal disease, were advised to wait until the age of 2 years before MenACWY-D vaccination. This recommendation was made as clinical trial data had noted that antibody levels decreased in 3 out of 7 pneumococcal vaccine strains when MenACWY-D was administered at the same time as Prevnar 7 (PCV7) pneumococcal vaccine.37
In June of 2012, the FDA approved the first meningococcal vaccine for use in infants as young as 6 weeks of age. MenHibrix (Hib-MenCY-TT), a meningococcal serogroup C and Y and Haemophilus b (HIB) tetanus toxoid conjugate vaccine manufactured by GlaxoSmithKline, received approval to be administered on a four dose schedule at 2, 4, 6, and 12 to 15 months of age.38 In response to FDA approval of MenHibrix (Hib-MenCY-TT), the CDC’s Advisory Committee on Immunization Practices approved the vaccine for use in infants with complement component deficiencies or anatomical or functional asplenia and for use in the event of an outbreak of meningococcal serogroup C or Y. It was not, however, recommended for use in infants or young children traveling to sub-Saharian Africa as the vaccine would offer no protection against meningococcal serogroups A and W-135 disease, the two most common serogroups found within this region. Routine vaccination of infants and young children was not recommended as MenHibrix (Hib-MenCY-TT) offered no protection against meningococcal serogroup B, the serogroup responsible for approximately 60 percent of all invasive meningococcal disease in infants and children under the age of 5 years. Further, with infants under 6 months of age considered most at risk of infection, public health officials believed that one or possibly two doses of the vaccine administered before 6 months of age would likely not impact meningococcal disease rates.39 Citing low demand for the product, GlaxoSmithKline announced the discontinuation of MenHibrix in the United States in October of 2016.40
In August of 2013, the FDA approved the use of Menveo (MenACWY-CRM) to be administered as a 4 dose series in infants at 2, 4, 6, and 12 to 15 months of age.41 Again, while routine vaccination of infants and young children was not recommended, the CDC’s Advisory Committee on Immunization Practices (ACIP) did, however, recommend the vaccine for use in infants and young children traveling to or residing in countries where meningococcal disease was considered endemic, during an outbreak of meningococcal disease for which the vaccine was indicated, in young children with complement component deficiencies, as well as for those with functional or anatomical asplenia. While simultaneous administration of Menactra (MenACWY-D) vaccine with Prevnar 7 (PCV7) vaccine was found to decrease pneumococcal antibody levels, this was not noted when Menveo (MenACWY-CRM) was administered concomitantly with PCV7 vaccine and therefore the vaccine was recommended for use in infants beginning at age 2 months who had received a diagnosis of functional or anatomical asplenia.42
The first meningococcal serogroup B vaccine, TRUMENBA, manufactured by Wyeth (Pfizer) pharmaceuticals, received FDA approval for use in persons aged 10 through 25 years of age on October 29, 2014.43 Less than 5 months earlier, TRUMENBA was given Breakthrough Therapy designation by the FDA and as meningococcal serogroup was considered a significant health threat, the FDA’s Center for Biologics Evaluation and Research (CBER) to agree to review TRUMENBA under the accelerated approval regulation. Pre-licensing clinical trials of TRUMENBA involved less than 4,600 healthy individuals predominantly between the ages of 11 and 18 years and the vaccine was only studied for safety and immunogenicity when administered with HPV4 vaccine. Pre-licensing clinical studies did not evaluated safety or immunogenicity of administering TRUMENBA with Tdap, influenza, HPV9 or any licensed meningococcal conjugate vaccines. 44
BEXSERO, a second meningococcal serogroup B vaccine, manufactured by Novartis Vaccines and Diagnostics (GlaxoSmithKline), received FDA approval for use on January 23, 2015.45 However, in late 2013 - early 2014, prior to FDA approval, the unlicensed vaccine was permitted by the CDC and FDA for use at both Princeton University and the University of California Santa Barbara (UCSB) where outbreaks of meningococcal serogroup B disease had been reported. At UCSB, where 51 percent of students received one vaccine dose and only 37 percent completed the recommended two dose series,46 no additional cases of meningococcal serogroup B disease were reported.47 At Princeton University, where 90 percent of students opted to receive 2 doses of the unlicensed vaccine, no further cases of meningococcal serogroup B disease were reported among vaccinated Princeton students but one additional case was reported in a student from another local university who had been in close contact with several Princeton University students.48 49 Vaccine researchers therefore concluded that while the vaccine appeared effective at protecting vaccinated individuals, it likely had no impact on nasopharyngeal carriage and vaccinated individuals could still potentially spread the disease to others. 50
BEXSERO also received Breakthrough Therapy designation by the FDA, and through the accelerated approval designation, it was licensed within 10 months. At the time of FDA approval, no clinical studies had examined the safety or immunogenicity of BEXSERO when administered concomitantly with any other vaccine.51
At the CDC’s February 2015 Advisory Committee on Immunization Practices (ACIP) meeting, the two newly licensed meningococcal group B (MenB) vaccines were recommended for use in persons 10 years and older with functional or anatomical asplenia, complement component deficiencies, as well as individuals taking eculizumab (Soliris®) medication, microbiologists routinely exposed to Neisseria meningitidis, and in the event of a meningococcal serogroup B disease outbreak.52 At the June 2015 ACIP meeting, the committee declined to routinely recommend MenB vaccines but stated that they could be administered to adolescents and young adults between the ages of 16 and 23 years of age, with the preferred age considered between 16 and 18 years. Routine MenB vaccination was not considered cost effective as data suggested that overall, it would only prevent between 15 and 29 cases, and 2 to 5 deaths, and among college students, approximately 9 cases and 1 death.53
In June 2016, HIV-positive individuals aged 2 months and older were added to the list of persons considered at high risk for meningococcal disease and recommended by the CDC’s Advisory Committee on Immunization Practices (ACIP) to receive meningococcal conjugate vaccines (serogroup A, C, Y and W-135). At the time of this recommendation, committee members admitted that there had never been any safety or immunogenicity studies of the vaccine for use in HIV-positive children aged 2 months to 2 years or among HIV-positive adults 25 years of age and older. Further, this decision was made despite conflicting data on meningococcal disease case-fatality rates. Studies from South Africa had noted a high meningococcal disease death rate among HIV-positive persons whereas studies from New York City and the United Kingdom had found lower death rates among HIV-positive individuals in comparison to persons without HIV disease.54
In February of 2017, Sanofi Pasteur announced the discontinuation of the Menomune tetravalent meningococcal polysaccharide vaccine. In response, the CDC announced that persons 56 years of age and older recommended to receive meningococcal vaccination be administered meningococcal conjugate vaccine. This recommendation was made despite acknowledging that neither available meningococcal conjugate vaccine is FDA approved for use in persons older than 55 years of age.55
On April 23, 2018, Pfizer (Wyeth) announced that its TRUMENBA meningococcal group B vaccine had once again received Breakthrough Therapy designation by the FDA. The designation involves the use of TRUMENBA in children 12 months through 9 years of age.56 FDA approval for use of the vaccine in this population is still currently pending.
NVIC “Quick Facts” is not a substitute for becoming fully informed about Meningococcal disease, meningitis and the Meningococcal vaccine. NVIC recommends consumers read the more complete information following the "Quick Facts", as well as the vaccine manufacturer product information inserts, and speak with one or more trusted health care professionals before making a vaccination decision for yourself or your child.
« Return to Vaccines & Diseases Table of Contents
1 Grabenstein JD, Pittman PR, Greenwood JT, Engler RJ. Immunization to protect the US Armed Forces: heritage, current practice, and prospects. Epidemiol Rev. 2006;28:3-26.
2 Artenstein AW, Opal JM, Opal SM et al. History of U.S. military contributions to the study of vaccines against infectious diseases. Mil Med. 2005 Apr;170(4 Suppl):3-11.
3 Artenstein MS Control of Meningococcal Meningitis with Meningococcal Vaccines Yale J Biol Med. 1975 Jul; 48(3): 197–200.
5 CDC Morbidity and mortality weekly report MMWR Nov. 8, 1975; 24(45); 381-382
7 Brundage JF, Ryan MA, Feighner BH, Erdtmann FJ. Meningococcal disease among United States military service members in relation to routine uses of vaccines with different serogroup-specific components, 1964-1998. Clin Infect Dis. 2002 Dec 1;35(11):1376-81.
8 CDC Meningococcal Disease - Meningococcal Vaccine Epidemiology and Prevention of Vaccine-Preventable Diseases (The Pink Book). 13th ed. 2015.
9 Brundage JF, Ryan MA, Feighner BH, Erdtmann FJ. Meningococcal disease among United States military service members in relation to routine uses of vaccines with different serogroup-specific components, 1964-1998. Clin Infect Dis. 2002 Dec 1;35(11):1376-81.
10 CDC Morbidity and mortality weekly report MMWR May 10, 1985; 34 (18); 255-259
11 CDC Meningococcal Disease and College Students - Recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Jun. 30, 2000; 49(RR07);11-20
12 FDA January 14, 2005 Approval Letter Jan. 14, 2005
13 CDC Prevention and Control of Meningococcal Disease Recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR May 27, 2005; 54(RR07);1-21
14 CDC Prevention and Control of Meningococcal Disease Recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR May 27, 2005; 54(RR07);1-21
15 FDA Clinical Review of New Biologics License Application - Menactra, January 14, 2005 Jan. 14, 2005
16 FDA Comparative Safety and Immunogenicity Study in Adults 18-55 year Old Clinical Study - Menactra Jan. 14, 2005
17 CDC FDA and CDC issue alert on Menactra meningococcal vaccine and Guillain Barre Syndrome Health Alert Network Sep. 30, 2005
18 CDC Morbidity and mortality weekly report MMWR Apr. 7, 2006; 55(13); 364-366
19 CDC Notice to Readers: Limited Supply of Meningococcal Conjugate Vaccine, Recommendation to Defer Vaccination of Persons Aged 11--12 Years MMWR May 26, 2006; 55(20);567-568
20 CDC Morbidity and mortality weekly report MMWR Oct. 20, 2006; 55(41); 1120-1124
21 CDC Meningococcal Disease - Contraindications and Precautions to Vaccination Epidemiology and Prevention of Vaccine-Preventable Diseases (The Pink Book). 13th ed. 2015.
22 FDA Menactra Product Insert Apr. 27, 2018
23 CDC Preventing Tetanus, Diphtheria, and Pertussis Among Adolescents: Use of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccines - Recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Mar. 24, 2006; 55(RR03);1-34
24 CDC CDC’s Advisory Committee Recommends Human Papillomavirus Virus Vaccination. Press Release. Jun.29, 2006
25 CDC Quadrivalent Human Papillomavirus Vaccine Recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR March 12, 2007; 56(Early Release);1-24
26 CDC Notice to Readers: Revised Recommendations of the Advisory Committee on Immunization Practices to Vaccinate All Persons Aged 11--18 Years with Meningococcal Conjugate Vaccine MMWR Aug. 10, 2007; 56(31);794-795
27 FDA October 18, 2007 Approval Letter Oct. 18, 2007
28 CDC Notice to Readers: Recommendation from the Advisory Committee on Immunization Practices (ACIP) for Use of Quadrivalent Meningococcal Conjugate Vaccine (MCV4) in Children Aged 2--10 Years at Increased Risk for Invasive Meningococcal Disease MMWR Dec. 7, 2007; 56(48);1265-1266
29 CDC Report from the Advisory Committee on Immunization Practices (ACIP): Decision Not to Recommend Routine Vaccination of All Children Aged 2--10 Years with Quadrivalent Meningococcal Conjugate Vaccine (MCV4) MMWR May 2, 2008; 57(17);462-465
30 FDA Feburary 19, 2010 Approval Letter – Menveo Feb. 19, 2010
31 CDC Licensure of a Meningococcal Conjugate Vaccine (Menveo) and Guidance for Use --- Advisory Committee on Immunization Practices (ACIP), 2010 MMWR Mar. 12, 2010; 59(09);273
32 FDA Statistical Review and Evaluation (Revised Summary and Conclusions) – Menveo Jan 13, 2010
33 CDC Updated Recommendations for Use of Meningococcal Conjugate Vaccines --- Advisory Committee on Immunization Practices (ACIP), 2010 MMWR Jan. 28, 2011; 60(03);72-76
35 FDA January 28, 2011 Approval Letter – Menevo Jan. 28, 2011
36 FDA April 22, 2011 Approval Letter – Menactra Apr. 22, 2011
37 CDC Recommendation of the Advisory Committee on Immunization Practices (ACIP) for Use of Quadrivalent Meningococcal Conjugate Vaccine (MenACWY-D) Among Children Aged 9 Through 23 Months at Increased Risk for Invasive Meningococcal Disease MMWR Oct. 14, 2011; 60(40);1391-1392
38 FDA June 14, 2012 Approval Letter – MenHibrix Jun. 14, 2012
39 CDC Infant Meningococcal Vaccination: Advisory Committee on Immunization Practices (ACIP) Recommendations and Rationale MMWR Jan. 25, 2013; 62(03);52-54
40 GSK MenHibrix Discontinuation Notice Oct. 2016
41 FDA August 1, 2013 Approval Letter – Menveo Aug. 1, 2013
42 CDC Use of MenACWY-CRM Vaccine in Children Aged 2 Through 23 Months at Increased Risk for Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2013 MMWR June 20, 2014; 63(24);527-530
43 FDA October 29, 2014 Approval Letter – TRUMENBA Oct. 29, 2014
44 FDA Summary Basis for Regulatory Action Oct. 29, 2014
45 FDA January 23, 2015 Approval Letter – BEXSERO Jan. 23, 2015
46 NFID Addressing the Challenges of Serogroup B Meningococcal Disease Outbreaks on Campuses: A Report by the National Foundation for Infectious Diseases May 2014
47 Soeters HM, McNamara LA, Blain AE et al. University-Based Outbreaks of Meningococcal Disease Caused by Serogroup B, United States, 2013–2018 Emerg Infect Dis. 2019 Mar; 25(3): 434–440.
48 McNamara LA, Shumate AM, Johnsen P et al. First Use of a Serogroup B Meningococcal Vaccine in the US in Response to a University Outbreak Pediatrics. 2015 May; 135(5): 798–804.
49 NFID Addressing the Challenges of Serogroup B Meningococcal Disease Outbreaks on Campuses: A Report by the National Foundation for Infectious Diseases May 2014
50 McNamara LA, Shumate AM, Johnsen P et al. First Use of a Serogroup B Meningococcal Vaccine in the US in Response to a University Outbreak Pediatrics. 2015 May; 135(5): 798–804.
51 FDA Summary Basis for Regulatory Action Jan. 23, 2015
52 CDC Use of Serogroup B Meningococcal Vaccines in Persons Aged ≥10 Years at Increased Risk for Serogroup B Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2015 MMWR June 12, 2015; 64(22);608-612
53 CDC Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults: Recommendations of the Advisory Committee on Immunization Practices, 2015 MMWR Oct. 23, 2015; 64(41);1171-6
54 CDC Recommendations for Use of Meningococcal Conjugate Vaccines in HIV-Infected Persons — Advisory Committee on Immunization Practices, 2016 MMWR Nov. 4, 2016; 65(43);1189–1194
55 CDC Clinical Update - Menomune (meningococcal polysaccharide vaccine) discontinuation Mar. 24, 2017
56 CDC PFIZER GRANTED FDA BREAKTHROUGH THERAPY DESIGNATION FOR TRUMENBA® (MENINGOCOCCAL GROUP B VACCINE) FOR THE PREVENTION OF INVASIVE MENINGOCOCCAL B DISEASE IN CHILDREN AGES 1 TO 9 YEARS Press Release Apr. 23, 2018